FDA Plans to Require REMS for Opioid Painkillers

The FDA plans to require risk evaluation and mitigation strategies for opioid analgesics — including immediate, extended-release and long-acting formulations — to ensure the benefits outweigh the risks of misuse, abuse, addiction, overdose and death.
Source: International Pharmaceutical Regulatory Monitor